Acrongenomics Inc. has launched its Nano-JETA Real Time PCR Pilot kits for DNA/RNA quantification with the use of beta-globin and Ep-CAM gene respectively.
The results obtained from previous validation and comparative studies bring Acrongenomics one step closer to finalizing its Nano-JETA technology platform by introducing its first Real Time PCR prototype kits. The kits apply to scientific professionals for demonstration purposes only in order for the company to obtain scientific feedback that will enhance the product’s usability and will establish the Nano-JETA platform.
The DNA/RNA quantification with the Nano-JETA technology platform is based on Acrongenomics’ new mathematical model. Furthermore, Nano-JETA Real Time PCR delivers rapid quantitative detection of nucleic acids from the 2nd cycle up to the 13th cycle.
Any Real Time PCR thermocycler with specifications to transmit fluorescence data according to Acrongenomics’ mathematical model is now able to quantify DNA/RNA copies at any point between the 2nd and 13th cycle, the release says.
The pilot kits allow for 24 tests to be performed. Furthermore, the kits contain— Certificate of Analysis (COA); Comprehensive Manual; General Mix (GM); Pre-Mix1 (PM1); Nano-JETA Master Mix (NJMM); New mathematical model required for quantification from the 2nd cycle.
Since last year, the Nano-JETA technology platform by Acrongenomics Inc. has redefined key IVD molecular applications such as PCR, ELISA and Real Time PCR giving them super fast characteristics with up to 100% specificity and sensitivity.
According to the company release, currently, Acrongenomics is working towards the enrichment of its portfolio with prototype kits for detection and quantification of additional tumour markers expression such as the HER family and vEGF, as well as, for viral quantification with markers such as EBV, HBV and HPV.
Molecular diagnostics testing is the fastest-growing segment of the in vitro diagnostics industry. The last four years, clinical market for molecular diagnostic products has increased from $1 billion in 2000 to $2.8 billion in 2004 and sales are expected to exceed $5 billion by 2008 (Biotechnology Associates).
Acrongenomics Inc. is a Research and Development nanobiotechnology company specializing in the development of ground-breaking nanomolecular diagnostic tools, to diagnose various diseases such as cancer of epithelial origin.